Project 4 Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$965,902	5
2024	Research	$1,135,662	4
2023	Research	$2,484,235	113
2022	Research	$1,268,572	14
2021	Research	$2,463,939	17
2020	Research	$144,454	8
2019	Research	$519,283	14

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca UK Limited $4,774,445 8 payments
AstraZeneca Pharmaceuticals LP $2,276,751 13 payments
Avanir Pharmaceuticals, Inc. $855,014 42 payments
E.R. Squibb & Sons, L.L.C. $797,054 3 payments
Chiesi USA, Inc. $267,484 107 payments
GlaxoSmithKline, LLC. $11,300 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $2,367,767 3 payments
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $2,210,137 5 payments
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $1,089,428 3 payments
A Phase II Randomized Openlabel Multicenter Doseranging Study in Adults and Pediatric Individuals 2265 12 years of Age to Assess the Safety Immunogenicity Pharmacokinetics and Pharmacodynamics of AZD7442 a Combination Product of Two Monoclonal Antibodies Tixagevimab and Cilgavimab for Pre-exposure Prophylaxis of COVID19 $1,060,579 3 payments
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $587,093 2 payments
15-Avp-786-303 $455,500 14 payments
AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD which enables the virus to bind to receptors on human cells. By targeting this region of the virus spike protein antibodies can block the virus attachment to human cells and therefore is expected to block infection. Amino acid substitutions have been introduced into the antibodies to both extend their half lives which should prolong their potential prophylactic benefit and decrease $271,971 6 payments
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $267,484 107 payments
17-Avp-786-205 $263,558 23 payments
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $209,960 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.